GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaccinex Inc (NAS:VCNX) » Definitions » Long-Term Debt & Capital Lease Obligation

Vaccinex (Vaccinex) Long-Term Debt & Capital Lease Obligation : $0.01 Mil (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Vaccinex Long-Term Debt & Capital Lease Obligation?

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Vaccinex's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.01 Mil.

LT-Debt-to-Total-Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligation divides by its Total Assets. Vaccinex's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.01 Mil. Vaccinex's Total Assets for the quarter that ended in Mar. 2024 was $7.37 Mil. Vaccinex's LT-Debt-to-Total-Asset for the quarter that ended in Mar. 2024 was 0.00.

Vaccinex's LT-Debt-to-Total-Asset declined from Mar. 2023 (0.04) to Mar. 2024 (0.00). It may suggest that Vaccinex is progressively becoming less dependent on debt to grow their business.


Vaccinex Long-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Vaccinex's Long-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaccinex Long-Term Debt & Capital Lease Obligation Chart

Vaccinex Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Long-Term Debt & Capital Lease Obligation
Get a 7-Day Free Trial - 1.13 0.18 0.25 0.03

Vaccinex Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Long-Term Debt & Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.19 0.13 0.07 0.03 0.01

Vaccinex Long-Term Debt & Capital Lease Obligation Calculation

Long-Term Debt is the debt due more than 12 months in the future. The debt can be owed to banks or bondholders. Some companies issue bonds to investors and pay interest on the bonds.

Long-Term Capital Lease Obligation represents the total liability for long-term leases lasting over one year. It's amount equal to the present value (the principal) at the beginning of the lease term less lease payments during the lease term.

The interest paid on companies' debt is reflected in the income statement as interest expense. If a company has too much debt and it cannot serve the interest payment on the debt or repay the matured debt, the company risks bankruptcy. Peter Lynch famously said: A company that does not have debt cannot go bankrupt.

A company's long term debt may have different dates of maturity and interest rates, depending on the terms.

Usually a company issues long term debt to pay for its capital expenditures. Borrowing allows the company to do things that otherwise cannot be done with only the capital it has. But debt can be risky.


Vaccinex  (NAS:VCNX) Long-Term Debt & Capital Lease Obligation Explanation

LT-Debt-to-Total-Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Vaccinex's LT-Debt-to-Total-Asset ratio for the quarter that ended in Mar. 2024 is calculated as:

LT-Debt-to-Total-Asset (Q: Mar. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )/Total Assets (Q: Mar. 2024 )
=0.006/7.367
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Buffett says that durable competitive advantages carry little to no long-term debt because the company is so profitable that even expansions or acquisitions are self financed.

We are interested in long term debt load for the last ten years. If the ten years of operation show little to no long term debt, then the company has some kind of strong competitive advantage.

Warren Buffett's historic purchases indicate that on any given year, the company should have sufficient yearly net earnings to pay all long term within 3 or 4 year earnings period. (e.g. Coke + Moody's = 1yr)

Companies with enough earning power to pay long term debt in less than 3 or 4 years is a good candidate in our search for long term competitive advantage.

BUT, these companies are targets for leveraged buy outs, which saddles the business with long term debt.

If all else indicates the company has a moat, but it has ton of debt, a leveraged buyout may have created the debt. In these cases the company's bonds offer the better bet, in that the company’s earnings power is focused on paying off the debt and not growth.

Important: little or no long term debt often means a Good Long Term Bet


Vaccinex Long-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Vaccinex's Long-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


Vaccinex (Vaccinex) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaccinex Inc (NAS:VCNX) » Definitions » Long-Term Debt & Capital Lease Obligation
Traded in Other Exchanges
N/A
Address
1895 Mount Hope Avenue, Rochester, NY, USA, 14620
Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb. The firm generates revenue from collaborative research, license, development and commercialization agreements.
Executives
Van Strydonck, Gerald E. director 1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
Maurice Zauderer director, 10 percent owner, officer: President and CEO 1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
Albert Friedberg director, 10 percent owner
Jacob B. Frieberg director 1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
Elizabeth E. Evans officer: Chief Operating Officer C/O VACCINEX, INC., 1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
Robert Scala officer: Chief Commercial Officer 1895 MT HOPE AVENUE, ROCHESTER NY 14620
Chrystyna Bedrij Stecyk director 1895 MT. HOPE AVENUE, ROCHESTER NY 14620
Vaccinex, Inc. director 1895 MOUNT HOPE AVE, ROCHESTER NY 14620
Jeff Goater director C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
Bala S Manian director 1025 TERRA BELLA AVE, MOUNTAIN VIEW CA 94043
Barbara Yanni director 1018 W. 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406
Alejandro M. Berlin director 1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
John E. Leonard officer: SVP, Development 1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
Ernest S. Smith officer: SVP, Research & CSO 1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
Raymond E. Watkins officer: SVP & Chief Operating Officer 1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620

Vaccinex (Vaccinex) Headlines

From GuruFocus

Vaccinex Announces $3.8 Million Private Placement

By Value_Insider Value_Insider 11-28-2022